Members of the ACCC IO Institute Executive Committee discuss why it’s essential to accommodate the unique side-effect profile for immunotherapy patients in survivorship care plans. (features Linda House, RN, BSN, MSM; and Jennie Crews, MD, MMM, FACP)
The dawn and evolution of immunotherapies have given rise to a new class of cancer survivors whose novel experience with these treatments require new tools and resources in survivorship. However, these patients are not typical candidates for receiving traditional survivorship care plans or resources. Current Commission on Cancer standards do not require cancer programs and practices to provide survivorship services to patients treated with immunotherapies. ACCC has created templates to help guide your programs and patients needs.
Explore Survivorship Templates
Survivorship in the Era of IO Lecture Series
Expert panels discuss the unique survivorship needs of IO patients, including improving care coordination and communication within the multidisciplinary team and how to meet patients’ psychosocial and physical well-being needs.
While immuno-oncology (IO) therapies have heralded significant advancements in cancer care, there are still many unknowns when it comes to the long-term side effects of these relatively new agents. Since ambulatory care typically involves long-term chronic disease management, these unknowns can often translate to management uncertainty.
The positive impacts of IO therapy are remarkable, the era of IO has also ushered in new challenges. The efficacy of IO has led to a growing population of patients living with and beyond cancer. This has challenged original concepts of survivorship care, starting with the very definition of “survivorship.”
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.